LADERX LLC

DURHAM, NC · CIK 0001970543 · Medtech · Private

Manganese-bisphosphonate MRI contrast agent for quantitative myocardial perfusion imaging

Grants
$300K
1 award
Sector median: 1
Raised
$67K
2 Form D · Apr 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$66,669
Federal grantDepartment of Health and Human Services · Phase I · Manganese-based MRI contrast agent for quantitative myocardial perfusion imaging$299,932
Private capital raisedForm D · SEC$3,000,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
800Tulavi Therapeutics, Inc.—$13M
801MICROVASCULAR TISSUES, INC.—$12M
802THERAHEART INC.—$12M
803LADERX LLC—$67K
804AVEERA MEDICAL INC.—$8.8M
805NANOCAN THERAPEUTICS CORPORATION—$6.2M
806XCath, Inc.—$5.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Banks ClarkExecutive Officer
  • Jeff ClarkExecutive Officer
  • Christopher LascolaExecutive Officer
  • Joseph McCaffreyExecutive Officer
  • Lanty SmithExecutive Officer
  • Margaret SmithExecutive Officer

Patents

USPTO · 0 granted of 1
  • Metal Complexes With Bisphosphonate Or Pyrophosphate Useful As Imaging Agentsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.